This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
(MedPage Today) -- LOS ANGELES -- Survival outcomes favored mechanical valves for isolated surgical aorticvalve replacement (SAVR) for people until age 60, after which a tissue valve may start to have an advantage, according to a large registry.
The NOTION trial, a pioneering study, sought to compare the long-term clinical and bioprosthesis outcomes of Transcatheter AorticValve Implantation (TAVI) versus Surgical AorticValve Replacement (SAVR) in patients with severe aorticvalve stenosis (AS) at lower surgical risk.
Getty Images milla1cf Fri, 06/07/2024 - 15:10 June 7, 2024 — Calcific aorticvalve disease (CAVD) is the major heart valve disease that afflicts nearly 10 million patients globally with an annual mortality exceeding 100,000, and the numbers continue to rise.
Genetic variants linked to a rare form of bicuspid aorticvalve disease that affects young adults and can lead to dangerous and potentially life-threatening aortic complications have been identified by researchers at UTHealth Houston.
This Viewpoint advocates for prompt aorticvalve replacement (rather than clinical surveillance) as the default strategy for patients with asymptomatic severe aortic stenosis.
milla1cf Tue, 12/12/2023 - 07:00 December 12, 2023 — Patients who received the anticoagulant drug warfarin after bioprosthetic aorticvalve replacement had lower incidence of mortality and a decreased risk of blood clots, according to a retrospective study published in Mayo Clinic Proceedings.
Valvular heart disease, including calcific or degenerative aortic stenosis (AS), is increasingly prevalent among the older adult population. Over the last few decades, treatment of severe AS has been revolutionised following the development of transcatheter aorticvalve replacement (TAVR).
Aortic Stenosis (AS) is a common condition with an estimated pooled prevalence of all AS in the elderly population at around 12.4%, with that of severe AS estimated to be around 3.4%. In the past, surgical aorticvalve replacement was the primary treatment option for severe AS for decades.
The decision between a bioprosthetic and mechanical valve is one of the most consequential for patients requiring aorticvalve replacement, said Michael Bowdish, MD, lead author of the study and a cardiothoracic surgeon at Cedars-Sinai Medical Center in Los Angeles.
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aorticvalve replacement (SAVR) for patients under age 65 with severe aortic stenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.
Objectives The clinical outcomes of transcatheter aorticvalve replacement (TAVR) in patients with aortic stenosis (AS) and concomitant active cancer remain insufficiently explored. This study aimed to assess the midterm outcomes of TAVR in patients diagnosed with AS and active cancer.
Large and rare duplications and deletions in a chromosome region known as 22q11.2 , which involves genes that regulate cardiac development, are linked to nonsyndromic bicuspid aorticvalve disease.
Transcatheter aorticvalve implantation (TAVI) was superior to surgical aorticvalve replacement for reducing death, stroke or rehospitalization in women with severe aortic stenosis, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.
This randomized clinical trial evaluates the safety and efficacy of administration of protamine to reduce bleeding following transcatheter aorticvalve implantation vs placebo, selective protamine administration.
What is the relationship between aorticvalve calcification (AVC) and aortic stenosis (AS) severity in patients with suspected low-flow low-gradient AS?
Background A quarter of patients with severe aortic stenosis (AS) were asymptomatic, and only a third of them survived at the end of 4 years. Only a select subset of these patients was recommended for aorticvalve replacement (AVR) by the current American College of Cardiology/American Heart Association guidelines.
He previously served on the HVS Board of Directors and has led the HVS AVIATOR Registry, an international registry examining outcomes after aorticvalve surgery. I am very excited and honored to lead the Heart Valve Society and further consolidate its role as a unique society dedicated to valvular heart disease.
In an era of rapidly expanding use of transcatheter aorticvalve implantation (TAVI), the management of patients with bicuspid aorticvalve (BAV) disease is far less well established than in those with trileaflet anatomy.
Objectives To evaluate the results of the inoperable and operable with aorticvalve endocarditis, focus on risk factors, significance, and management of destruction of the aortic annulus in aorticvalve endocarditis.
Background Closure of paravalvular leak (PVL) regurgitation after self-expandable (SE) transcatheter aorticvalve implantation (TAVI) may be more challenging than after balloon-expandable (BE) valve implantation. MN, USA).
This cohort study examines whether there is an association between osteosarcopenia and adverse outcomes, such as increased risk of mortality, in older adults following transcatheter aorticvalve replacement (TAVR).
A transthoracic echocardiogram (TTE) revealed a mobile mass on the right coronary cusp of the aorticvalve ( figure 1 , ). cm) at the right coronary cusp of the aorticvalve on the long-axis and short-axis parasternal view. Figure 1 A mobile mass (1.88 Question What is the most likely diagnosis?
Transcatheter aorticvalve replacement (TAVR) is the standard treatment for severe aortic stenosis, but post-TAVR leaflet thrombus, identified by hypoattenuated leaflet thickening (HALT), poses potential risks like cerebral thromboembolic events. had thrombus at any aorticvalve complex. Specifically, 14.2%
BACKGROUND:A high permanent pacemaker implantation (PPI) risk remains a concern of self-expandable transcatheter aorticvalve implantation, despite the continued improvements in implantation methodology. There were no group differences in 30-day all-cause mortality (1.4% versus 0%;P=0.608).CONCLUSIONS:Our
The goal of the AVATAR trial was to evaluate aorticvalve replacement (AVR) compared with conservative therapy among patients with asymptomatic severe aortic stenosis.
Valvosoft is designed to non-invasively restore leaflet mobility in a stenotic aorticvalve and widen the valve opening to relieve patient heart failure symptoms. High-intensity focused ultrasound waves micro-fracture calcification embedded in aorticvalve leaflets without damaging tissue.
Bicuspid aorticvalve (BAV), the most common congenital cardiac anomaly, predisposes individuals to aortic stenosis and regurgitation due to valve degeneration.
1, 2024 — Researchers at UTHealth Houston have identified genetic variants linked to a rare form of bicuspid aorticvalve disease that affects young adults and can lead to dangerous and potentially life-threatening aortic complications. tim.hodson Wed, 09/04/2024 - 15:53 Sept.
This is a case report of a 78-year-old male who underwent a sub-coronary aorticvalve and root replacement due to valve dehiscence and aortic root pseudoaneurysm. The patient had complex anomalous coronary ana.
(MedPage Today) -- Transcatheter aorticvalve replacement (TAVR) yielded clinical benefit when given early in the disease process while patients still had no symptoms or other indication for aorticvalve replacement, according to the EARLY TAVR.
(MedPage Today) -- SAN ANTONIO -- The early experience of patients needing cardiac surgery after transcatheter aorticvalve replacement (TAVR) has surgeons raising the alarm about the excess risks of these challenging procedures, based on data.
Transcatheter aorticvalve replacement (TAVR) has increased in utilization since its approval for management of aortic stenosis patients across all risk strata. We report a rare case of aorticvalve leaflet av.
The goal of the NOTION-3 trial was to evaluate percutaneous coronary intervention (PCI) compared with conservative therapy among patients with obstructive coronary artery disease undergoing transcatheter aorticvalve implantation (TAVI).
Blaha, MD, MPH discuss Prevalence of AorticValve Calcium and the Long-Term Risk of Incident Severe Aortic Stenosis. In this interview, Richard A. Chazal MD, MACC and Michael J.
Bicuspid aorticvalve (BAV) is a common congenital heart condition that can lead to some valve-related complications, such as aortic stenosis and/or regurgitation, and is often associated with aortic root dilation.
The following are key points to remember from a state-of-the-art review on sutureless valves, a “wireless†option for patients with aorticvalve disease.
Recently published research shows a medical device may be beneficial for patients who have previously had a stroke and are planning to undergo a transcatheter aorticvalve replacement, a type of heart valve operation.
The goal of the DEDICATE-DZHK6 trial was to evaluate transcatheter aorticvalve implantation (TAVI) compared with surgical aorticvalve replacement (SAVR) among patients with severe aortic stenosis and low to intermediate surgical risk.
Transcatheter aorticvalve replacement (TAVR) is a relatively new treatment method for aortic stenosis (AS) and has been demonstrated to be suitable for patients with varying risk levels.
Getty Images milla1cf Wed, 05/15/2024 - 19:10 May 15, 2024 — A new study demonstrated parity between a minimally invasive procedure to replace the aorticvalve in the heart— transcatheter aorticvalve replacement (TAVR)—and surgical aorticvalve replacement (SAVR).
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content